Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Methods of Documentation VI: Case Management Model01:15

Methods of Documentation VI: Case Management Model

682
The case management model is a multidisciplinary approach that involves healthcare professionals from diverse disciplines, such as physicians, nurses, therapists, social workers, and pharmacists, working collaboratively to address the various needs of patients. Each healthcare professional brings unique expertise and perspectives, contributing to a more comprehensive understanding of the patient's condition and tailoring treatment plans accordingly.
For example, a patient with a chronic...
682
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

167
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
167
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

609
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
609
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Multipotency of Hematopoietic Stem Cells01:19

Multipotency of Hematopoietic Stem Cells

3.5K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.5K
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

154
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
154

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Authors' reply to 'Comments on dose-dependent impairment of brain functional and microstructural connectivity during leukaemia chemotherapy'.

British journal of haematology·2026
Same author

Single cell long read genotyping of transcripts reveals discrete mechanisms of clonal evolution in post-MPN AML.

Blood advances·2026
Same author

Dose-dependent impairment of brain functional and microstructural connectivity during leukaemia chemotherapy.

British journal of haematology·2026
Same author

Uncommon Evolution From Acute Myeloid Leukaemia to <i>JAK2</i>-Mutated Myeloproliferative Neoplasm: Evidence of Clonal Persistence and Divergence From <i>TET2</i>/<i>SRSF2</i>-Mutated Haematopoietic Progenitors.

EJHaem·2025
Same authorSame journal

Impact of the clinical nurse specialist role for the myeloproliferative neoplasm program: Part Two - The team and patient care experiences.

Canadian oncology nursing journal = Revue canadienne de nursing oncologique·2025
Same author

Impact of the clinical nurse specialist role for the myeloproliferative neoplasm program: Part One - From timeliness of triage to cost-saving.

Canadian oncology nursing journal = Revue canadienne de nursing oncologique·2025

Related Experiment Video

Updated: Nov 4, 2025

Modeling Chemotherapy Resistant Leukemia In Vitro
08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

9.3K

Shared-care model for complex chronic haematological malignancies.

Verna Cheung1, Nancy Siddiq2, Rebecca Devlin3

  • 1Clinical Nurse Specialist, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON.

Canadian Oncology Nursing Journal = Revue Canadienne De Nursing Oncologique
|May 26, 2021
PubMed
Summary
This summary is machine-generated.

This study introduces a shared-care model for myeloproliferative neoplasms (MPNs), rare leukemias, to reduce patient travel burdens and improve quality of life by providing expert care closer to home.

Keywords:
care delivery modelschronic leukemiahematological malignanciesmyeloproliferative neoplasmsshared-care

More Related Videos

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.6K
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.9K

Related Experiment Videos

Last Updated: Nov 4, 2025

Modeling Chemotherapy Resistant Leukemia In Vitro
08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

9.3K
Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.6K
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.9K

Area of Science:

  • Hematology
  • Oncology
  • Public Health

Background:

  • Myeloproliferative neoplasms (MPNs) are rare chronic leukemias requiring specialized care.
  • Limited expertise in MPNs is concentrated in specialist centers, leading to patient travel burdens and reduced quality of life.
  • Existing care models pose financial and logistical challenges for patients and caregivers.

Purpose of the Study:

  • To describe the implementation and experience of a shared-care model for MPN patients.
  • To reduce the burden on patients by providing care closer to home.
  • To maintain high-quality, patient-centered care through collaboration.

Main Methods:

  • Implementation of a shared-care model involving collaboration with local healthcare providers.
  • Ongoing management and supportive care delivery for MPN patients within the shared-care framework.
  • Evaluation of the model's impact on patient travel burden and quality of care.

Main Results:

  • The shared-care model successfully decreased patient travel burden.
  • High-quality, patient-centered care was maintained through the collaborative approach.
  • The model facilitates accessible care for MPN patients within their local communities.

Conclusions:

  • Shared-care models can effectively manage rare chronic diseases like MPNs.
  • This approach enhances patient accessibility to specialized care while reducing logistical challenges.
  • The model is potentially adaptable for other rare chronic hematological malignancies and diseases.